bevacizumab + FOLFOXIRI

bevacizumab + FOLFOXIRI is a potent combination chemotherapy regimen used primarily in the treatment of metastatic colorectal cancer. It combines bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A) to inhibit tumor angiogenesis, with the FOLFOXIRI backbone. FOLFOXIRI is a triplet cytotoxic regimen consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and irinotecan. This combination is often utilized as a standard-of-care comparator or a backbone therapy in clinical trials evaluating novel agents, such as CSPC Megalith Biopharmaceutical's SYS6090, particularly in patients with mismatch repair-proficient (pMMR) or microsatellite stable (MSS) colorectal cancer who require aggressive frontline treatment.

Brand names

Avastin

Other names

bevacizumab plus FOLFOXIRIbevacizumab, 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan